As far as NWBO’s brain cancer clinical trial, it looks there are certain groups for whom it has extremely good results. 3 years of life instead of 2 is, in my book, worth undergoing this treatment. I’ve put these quotes out of order from the article, so that the impatient readers here see the important stuff before they quit reading.

Quote:

---

Thirteen percent of patients treated with the vaccine survived at least five years from diagnosis compared to 5.7% in the control group, with the longest survivor surpassing eight years . Patients with methylated MGMT gene who were treated with the vaccine survived 30.2 months on average from randomization in the trial (33 months from surgery) compared to 21.3 months for the control group.

Patients with recurrent glioblastoma who were treated with the vaccine survived 13.2 months on average, compared to 7.8 months for the control group..

---

Quote:

---

A vaccine (DCVax-L), trialed at King's College Hospital and other centers around the world, using patients' immune cells to target brain cancer can extend survival by many months or, in some cases, years, the final unblinded results from a phase 3 clinical trial has shown. The final results were published on Thursday, November 17 in JAMA Oncology.

This is the first time in 17 years that such significant outcomes have been achieved in a phase 3 trial for a systemic treatment in newly diagnosed glioblastoma, and the first time in 27 years that any treatment has been shown to extend survival in recurrent glioblastoma.

---

https://medicine.net/news/Worldmedicine/5225.html